Synopsis

The success of GLP-1 receptor agonists has significantly advanced obesity treatment, yet there remains a vast potential for further innovation by targeting new pathways. This theme is dedicated to uncovering and exploring novel biological targets beyond GLP-1 that hold the promise to revolutionize obesity therapeutics. By investigating cutting-edge research on alternative receptors, signalling pathways, and metabolic processes, this session aims to identify breakthrough targets that can deliver superior efficacy, reduced side effects, and enhanced patient outcomes.

Synopsis

• Explore how understanding adipose tissue biology can lead to the development of novel obesity treatments that target fat cells directly
• Discuss recent advancements in therapies aimed at reducing adipose tissue, focusing on the efficacy and safety profiles of these innovative approaches
• Demonstrating the impact of adipose-targeted treatments on weight loss and metabolic health

Synopsis

• Uncover the unique approach to obesity treatment with nimacimab, a first-in-class peripheral CB1 inhibitor, by modulating energy expenditure and fat metabolism, while preserving muscle mass
• Discover the potential of nimacimab to offer a safer, more tolerable weight loss option with a favorable gastrointestinal profile and minimal neuropsychiatric side effects, addressing common concerns associated with current obesity treatments
• Explore the latest clinical developments of nimacimab, including its upcoming Phase 2 study designed to evaluate its efficacy in promoting sustainable weight loss and improving metabolic health, both as a monotherapy and in combination with GLP-1 agonists

Synopsis

• Delve into how ATX-304 activates AMPK and mitochondrial pathways to enhance energy expenditure, glucose, and lipid metabolism
• Review the ongoing Phase 1B study results in pre-diabetic, overweight/obese subjects, focusing on ATX-304’s effects on metabolic health and its potential role in chronic weight management

Synopsis

• Learn how ADPO-002NP, a Notch signaling inhibitor, promotes the browning of subcutaneous, energy-storing white fat into healthier, energy-burning fat, as a novel approach to increase calorie expenditure.
• Uncover the potential systemic impacts of the creation and activation of subcutaneous brown fat, including full-body weight loss, improved glucose control, decreased circulating lipids, and reduced liver fat, demonstrating the potential for broad metabolic benefits.
• Explore evidence from human adipose tissue studies showing significant increases in key browning biomarkers with ADPO-002 treatment, providing strong support for clinical translation to the treatment of obesity in people.

Synopsis

• Detailing GLY-200 a first-in-class, orally-administered polymer therapy designed to modulate the mucosal barrier in the GI tract, mimicking the therapeutic effects of gastric bypass surgery without the need for invasive procedures
• Examining current state of play with ongoing phase 2 trial demonstrating the potential of GLY-200 to deliver disease-modifying benefits for T2D and obesity, offering a safer, more accessible alternative to metabolic surgery
• Increasing accessibility of powerful metabolic disease treatments with non-invasive, cost-effective solution for patients who cannot undergo traditional surgical interventions

Synopsis

• Delve into Equator Therapeutics’ development of a novel candidate drug that stimulates thermogenesis, the body’s natural heat production, as a new mechanism to combat obesity and metabolic disorders
• Explore the use of advanced mitochondrial assays to identify and optimize compounds that safely and effectively activate thermogenesis
• Discuss the broader implications of mitochondrial modulation in treating metabolic disorders

Synopsis

As we stand on the brink of a new era in obesity treatment, the question remains: What will define the next generation of obesity therapeutics? With the rapid advancements in GLP-1 agonists, the emergence of novel targets, and the growing interest in combination and sequential therapies, the landscape is evolving at an unprecedented pace.

This interactive session gives you the opportunity to be part of the discussion, get ready to share ideas and learn from your peers. Amongst your tables talking points to consider include:

• How can we optimize GLP-1 receptor agonists to enhance efficacy, safety, and patient adherence?
• What novel targets hold the most promise for the next wave of obesity therapeutics?
• Do we see combinatory approaches revolutionizing obesity treatment? What synergies should we be exploring to maximize therapeutic outcomes?
• How can sequential therapies be structured to offer sustained weight loss and long-term metabolic benefits?

Join your peers in this roundtable discussion to brainstorm, share insights, and collectively envision the next breakthroughs!

Synopsis

• Exploring GDD3898, Lipidio’s novel compound, works by inhibiting SCD-1 specifically in the skin, offering a novel approach to treating obesity through localized mechanisms that impact systemic metabolism
• Exploring the reduction in fat storage and enhancement of energy expenditure by targeting SCD-1, detailing a new class of therapeutic that act through the skin rather than traditional systemic pathways